Ameriprise
ASND icon

Ameriprise’s Ascendis Pharma A/S ASND Stock Holding History

Ameriprise’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.5M Sell
320,514
-155,952
-33% -$36.4M 0.02% 671
2026
Q1 		$109M Sell
476,466
-74,011
-13% -$16.6M 0.03% 527
2025
Q4 		$117M Sell
550,477
-12,459
-2% -$2.57M 0.03% 506
2025
Q3 		$112M Sell
562,936
-25,133
-4% -$4.69M 0.03% 525
2025
Q2 		$102M Sell
588,069
-91,874
-14% -$15M 0.03% 546
2025
Q1 		$106M Sell
679,943
-22,618
-3% -$3.23M 0.03% 517
2024
Q4 		$96.7M Buy
702,561
+32,844
+5% +$4.32M 0.02% 560
2024
Q3 		$100M Buy
669,717
+9,055
+1% +$1.22M 0.03% 548
2024
Q2 		$90.1M Buy
660,662
+605,496
+1,098% +$82.4M 0.02% 559
2024
Q1 		$8.34M Sell
55,166
-7,144
-11% -$1.02M ﹤0.01% 1952
2023
Q4 		$7.85M Buy
62,310
+1,734
+3% +$173K ﹤0.01% 1993
2023
Q3 		$5.67M Sell
60,576
-8,043
-12% -$752K ﹤0.01% 2183
2023
Q2 		$6.12M Buy
68,619
+14,586
+27% +$1.27M ﹤0.01% 2183
2023
Q1 		$5.79M Sell
54,033
-103
-0.2% -$11.8K ﹤0.01% 2214
2022
Q4 		$6.61M Sell
54,136
-331
-0.6% -$38.4K ﹤0.01% 2088
2022
Q3 		$5.63M Buy
54,467
+4,302
+9% +$408K ﹤0.01% 2126
2022
Q2 		$4.66M Sell
50,165
-1,644
-3% -$155K ﹤0.01% 2334
2022
Q1 		$6.08M Buy
51,809
+3,232
+7% +$374K ﹤0.01% 2293
2021
Q4 		$6.54M Sell
48,577
-2,610
-5% -$388K ﹤0.01% 2281
2021
Q3 		$8.16M Sell
51,187
-1,344
-3% -$184K ﹤0.01% 2026
2021
Q2 		$6.91M Buy
52,531
+4,494
+9% +$599K ﹤0.01% 2221
2021
Q1 		$6.19M Sell
48,037
-22,119
-32% -$3.36M ﹤0.01% 2259
2020
Q4 		$11.7M Sell
70,156
-2,674
-4% -$442K ﹤0.01% 1631
2020
Q3 		$11.2M Sell
72,830
-933
-1% -$134K ﹤0.01% 1476
2020
Q2 		$10.9M Buy
73,763
+61
+0.1% +$8.38K ﹤0.01% 1477
2020
Q1 		$8.3M Sell
73,702
-24,731
-25% -$3.21M ﹤0.01% 1531
2019
Q4 		$13.7M Buy
98,433
+240
+0.2% +$26.7K 0.01% 1488
2019
Q3 		$9.46M Sell
98,193
-7,838
-7% -$874K ﹤0.01% 1737
2019
Q2 		$12.2M Buy
106,031
+42,448
+67% +$5.08M 0.01% 1570
2019
Q1 		$7.48M Buy
+63,583
New +$5.57M ﹤0.01% 1935

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Ameriprise's ASND Position: Q2 2026 in Review

Ameriprise reduced its Ascendis Pharma A/S (ASND) stake by 33% in Q2 2026, selling an estimated $36.4M and leaving 320,514 shares worth $85.5M. The position accounts for 0.02% of the portfolio, ranked #671.

Ameriprise first reported a position in ASND in Q1 2019 and has held it in 30 quarters since. The position peaked at $117M in Q4 2025. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Ameriprise held 320,514 shares of Ascendis Pharma A/S worth $85.5M as of Q2 2026.
  • Ameriprise sold 155,952 Ascendis Pharma A/S shares in Q2 2026, an estimated $36.4M.
  • Ascendis Pharma A/S made up 0.02% of Ameriprise's portfolio in Q2 2026, its #671 holding.
  • Ameriprise first reported a position in Ascendis Pharma A/S in Q1 2019 and has held it in 30 quarters since.
  • Ameriprise's Ascendis Pharma A/S position peaked at $117M in Q4 2025.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.